A Dose-escalation Study in Subjects With Advanced Malignancies
NCT01195311
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumors and Hematologic Malignancy
Interventions
DRUG:
INCB024360
Sponsor
Incyte Corporation